
Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

4

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



01 JAN 22 PM 3:51

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name		
Akin, Gump, Strauss, Hauer & Feld, L.L.P.		
2. Address () Check if different than previously reported		
1333 New Hampshire Avenue, NW		
3. Principal Place of Business (if different from line 2)		
City: Washington State/Zip (or	Country) DC 20036	
4. Contact Name Telephone	E-mail (optional) 5. Senate ID #	
Donald R. Pongrace 202-887-4000	682-862	
7. Client Name Self	6. House ID #	
Pfizer, Inc.	31784036	
TYPE OF REPORT 8. Year 2000 Midyear 9. Check if this filing amends a previously filed version of this 10. Check if this is a Termination Report	_	
	TO RO Embrying Activity [1]	
INCOME OR EXPENSES - Complete Either	Line 12 OR Line 13	
12. Lobbying Firms	13. Organizations	
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:	
Less than \$10,000	Less than \$10,000 []]	
5₹0,000 or more	\$10,000 or more	
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.	
	Method A. Reporting amounts using LDA definitions only	
	Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code	
	C) Method C. Reporting amounts under section 162(e) of the internal Revenue Code	
Signature		
Printed Name and Title Donald R. Pongrace, Partner	······································	
LINT (REV. 6/98)	PAGE 1 of 3	

	Attach additional page(s) as no	coucu.	
15. General issue area cod	te TRA (one per page)		
16. Specific lobbying issu	ees		
Potential legislation of	or regulation regarding use of c	ertain antihistamines by operators of commercial	vehicles
17 *¥aua(a) aF.C			
U.S. House of Represei U.S. Senate U.S. Department of Tra		d : Check if None	
18. Name of each individu	al who acted as a lobbyist in the	E	١,,
 Name of each individual Charles W. Johnson, IV 	Name	his issue area Covered Official Positium (if applicable)	N.
Charles W. Johnson, IV	Name (Covered Official Position (if applicable)	
Charles W. Johnson, IV Susan H. Lent Donald R. Pongrace	Name	Covered Official Position (if applicable)	
Charles W. Johnson, IV Susan H. Lent Donald R. Pongrace Henry A. Terhune	Name	Covered Official Position (if applicable)	
Charles W. Johnson, IV Susan H. Lent Donald R. Pongrace Henry A. Terhune	Name	Covered Official Position (if applicable)	
Charles W. Johnson, IV Susan H. Lent Donald R. Pongrace Henry A. Terhune	Name	Covered Official Position (if applicable)	
Charles W. Johnson, IV Susan H. Lent Donald R. Pongrace Henry A. Terhune	Name	Covered Official Position (if applicable)	
Charles W. Johnson, IV Susan H. Lent Donald R. Pongrace Henry A. Terhune	Name	Covered Official Position (if applicable)	
Charles W. Johnson, IV Susan H. Lent Donald R. Pongrace Henry A. Terhune	Name	Covered Official Position (if applicable)	

Registrant Name Akin, Gump, Strauss, Hatter & Feld, L.L.P.	Client Name Pfizer, Inc.	
LOBBYING ACTIVITY. Select as many codes as necess engaged in lobbying on behalf of the client during the repoinformation as requested. Attach additional page(s) as need	ary to reflect the general issue areas in which the registrant rting period. Using a separate page for each code, provide ded.	:
15. General issue area code <u>HCR</u> (one per page)		
16. Specific lobbying issues Legislation relating to Medicare prescription drug ben	efit, including Medicare Rx 2000 Act, H.R. 4680	
17. House(s) of Congress and Federal Agencies contacted U.S. House of Representatives U.S. Senate	[] Check if None	
18. Name of each individual who acted as a lobbyist in this	1	
Smith W. Davis	Covered Official Position (if applicable) New	
Karen E. Goldmeier		
Gary A. Heimberg		
Jorge Lopez, Jr.		-
Donald R. Pongrace		
		•
19. Interest of each foreign entity in the specific issues listed on I	ine 16 above Check if None	